Roche wins EU approval for Susvimo as wet AMD treatment burden becomes the next battleground
The European Commission has approved Roche’s Susvimo implant for neovascular age-related macular degeneration, offering continuous ranibizumab delivery with refills every six months and creating a fundamentally different alternative to repeated eye injections.
